Free Trial

Alliance Pharma (APH) Competitors

GBX 36.20
-1.30 (-3.47%)
(As of 07/15/2024 ET)

APH vs. AMYT, BMK, AGY, BXP, ANCR, EAH, DNL, CEL, PXS, and STX

Should you be buying Alliance Pharma stock or one of its competitors? The main competitors of Alliance Pharma include Amryt Pharma (AMYT), Benchmark (BMK), Allergy Therapeutics (AGY), Beximco Pharmaceuticals (BXP), Animalcare Group (ANCR), ECO Animal Health Group (EAH), Diurnal Group (DNL), Celadon Pharmaceuticals (CEL), Provexis (PXS), and Shield Therapeutics (STX). These companies are all part of the "drug manufacturers - specialty & generic" industry.

Alliance Pharma vs.

Amryt Pharma (LON:AMYT) and Alliance Pharma (LON:APH) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations, community ranking and media sentiment.

Amryt Pharma received 40 more outperform votes than Alliance Pharma when rated by MarketBeat users. Likewise, 65.68% of users gave Amryt Pharma an outperform vote while only 62.08% of users gave Alliance Pharma an outperform vote.

CompanyUnderperformOutperform
Amryt PharmaOutperform Votes
243
65.68%
Underperform Votes
127
34.32%
Alliance PharmaOutperform Votes
203
62.08%
Underperform Votes
124
37.92%

Amryt Pharma has higher revenue and earnings than Alliance Pharma. Alliance Pharma is trading at a lower price-to-earnings ratio than Amryt Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amryt Pharma£210.24M0.00N/A-£33.00N/A
Alliance Pharma£170.05M1.15-£7.06M-£0.01-3,620.00

Amryt Pharma has a net margin of 0.00% compared to Amryt Pharma's net margin of -4.15%. Alliance Pharma's return on equity of 0.00% beat Amryt Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Amryt PharmaN/A N/A N/A
Alliance Pharma -4.15%-2.46%2.99%

68.3% of Alliance Pharma shares are owned by institutional investors. 11.8% of Alliance Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Alliance Pharma's average media sentiment score of 0.00 equaled Amryt Pharma'saverage media sentiment score.

Company Overall Sentiment
Amryt Pharma Neutral
Alliance Pharma Neutral

Alliance Pharma has a consensus target price of GBX 56.50, suggesting a potential upside of 56.08%.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amryt Pharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Alliance Pharma
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50

Summary

Amryt Pharma beats Alliance Pharma on 6 of the 11 factors compared between the two stocks.

Get Alliance Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for APH and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

APH vs. The Competition

MetricAlliance PharmaDrug Manufacturers IndustryMedical SectorLON Exchange
Market Cap£195.63M£1.26B£5.30B£1.48B
Dividend Yield3.75%3.07%5.26%11.99%
P/E Ratio-3,620.00340.47132.491,696.28
Price / Sales1.156,078.722,213.01306,163.75
Price / Cash7.8710.3432.4734.12
Price / Book0.715.714.952.68
Net Income-£7.06M£151.81M£108.49M£173.45M
7 Day Performance-1.50%0.78%5.62%0.87%
1 Month Performance8.06%63.40%6.19%3.06%
1 Year Performance-20.96%100.79%6.73%20.63%

Alliance Pharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AMYT
Amryt Pharma
0 of 5 stars
0.00 / 5 stars
GBX 143
-11.7%
N/A+0.0%£457.11M£210.24M-4.332,020Gap Down
BMK
Benchmark
0 of 5 stars
0.00 / 5 stars
GBX 38.65
-1.5%
N/A-3.6%£285.91M£155.53M-1,288.33823Gap Down
AGY
Allergy Therapeutics
0 of 5 stars
0.00 / 5 stars
GBX 5.58
+3.3%
N/A+165.7%£266.17M£53.26M-93.00612Gap Up
BXP
Beximco Pharmaceuticals
0 of 5 stars
0.00 / 5 stars
GBX 38.50
flat
N/A+5.5%£171.75M£43.08B481.255,700
ANCR
Animalcare Group
0 of 5 stars
0.00 / 5 stars
GBX 235
flat
N/A+32.4%£141.87M£74.35M11,750.00220High Trading Volume
EAH
ECO Animal Health Group
0 of 5 stars
0.00 / 5 stars
GBX 127
flat
N/A+18.1%£86.03M£88.46M-6,350.00234Analyst Forecast
News Coverage
DNL
Diurnal Group
0 of 5 stars
0.00 / 5 stars
N/AN/AN/A£46.33M£4.68M-3.2133
CEL
Celadon Pharmaceuticals
0 of 5 stars
0.00 / 5 stars
GBX 59.50
-9.8%
GBX 235
+295.0%
-59.7%£39.12M£11,258.00-425.0024News Coverage
High Trading Volume
PXS
Provexis
0 of 5 stars
0.00 / 5 stars
GBX 0.58
-5.0%
N/A-11.5%£13.00M£426,168.0043.752
STX
Shield Therapeutics
0 of 5 stars
0.00 / 5 stars
GBX 1.65
flat
N/A-74.7%£12.90M£7.40M-13.7527

Related Companies and Tools

This page (LON:APH) was last updated on 7/15/2024 by MarketBeat.com Staff

From Our Partners